CDC37 and cancer: Targeting the Hsp90–Cdc37 PPI offers several compelling therapeutic advantages over traditional strategies that inhibit Hsp90's ATPase activity.5,13 By disrupting this critical interaction selectively, these inhibitors achieve more refined modulation of chaperone activity with improved specificity, reduced systemic toxicity, and the potential to overcome resistance mechanisms often encountered in cancer therapy.75,76